Levamisole news

All news on Levamisole: plants, production capacities, investments and involved companies.

13 February 2026

EMA Recommends Withdrawal of Levamisole Medicines

Levamisole's risks, including leukoencephalopathy, outweigh benefits for treating parasitic infections. EMA advises EU market withdrawal due to safety concerns.

Who will be producing Levamisole in the future?

Find out with chemXplore Analytics